Irreproducibility –The deadly sin of preclinical research in drug development
Introduction In recent years the irreproducibility of preclinical studies has become a serious concern in drug developmental research. The findings of preclinical studies that cannot be reproduced are a drain on public resources and slow down the drug discovery process. Among the various factors tha...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Institute of Rural Health
2020-12-01
|
| Series: | Journal of Pre-Clinical and Clinical Research |
| Subjects: | |
| Online Access: | https://www.jpccr.eu/Irreproducibility-The-deadly-sin-of-preclinical-research-in-drug-development,131017,0,2.html |
| _version_ | 1797870229550792704 |
|---|---|
| author | Sadasivan Kalathil Pillai Katsumi Kobayashi Mathews Michael Meena Arumugam |
| author_facet | Sadasivan Kalathil Pillai Katsumi Kobayashi Mathews Michael Meena Arumugam |
| author_sort | Sadasivan Kalathil Pillai |
| collection | DOAJ |
| description | Introduction
In recent years the irreproducibility of preclinical studies has become a serious concern in drug developmental research. The findings of preclinical studies that cannot be reproduced are a drain on public resources and slow down the drug discovery process. Among the various factors that contribute to irreproducibility in preclinical drug developmental research, poor statistical analysis and weak experimental design play a major role in the failure of drugs in clinical research. Conclusion. Poor experimental design and lack of knowledge or limited knowledge of statistical analysis of data contribute significantly to the irreproducibility of preclinical research. A well-designed experiment with proper statistical analysis of data conducted by committed researchers rarely fails to reproduce.
Objective
The aim of this review is to describe key factors, such as poor statistical analysis and weak experimental design, that contribute to the irreproducibility of preclinical studies in drug development, and how such studies slow down the drug development process.
Brief description of the state of knowledge
Theirreproducibility of preclinical research is a serious issue that researchers, especially those who are involved in drug discovery, are facing today. The irreproducibility of research drains public resources, time, and diminish the trust of the common man in the research community. The factors that contribute to the irreproducibility of preclinical research are related to experiment design and improper statistical analysis of the experimental data. Most of these factors can be eliminated by researchers developing a commitment to science and society.
Conclusions
Poor experimental design and lack of knowledge or limited knowledge of statistical analysis of data contribute significantly to the irreproducibility of preclinical research. A well-designed experiment with proper statistical analysis of data conducted by committed researchers rarely fails to reproduce. |
| first_indexed | 2024-04-10T00:25:08Z |
| format | Article |
| id | doaj.art-3cf67d6b422047818856a4c0ce6b965d |
| institution | Directory Open Access Journal |
| issn | 1898-2395 1898-7516 |
| language | English |
| last_indexed | 2024-04-10T00:25:08Z |
| publishDate | 2020-12-01 |
| publisher | Institute of Rural Health |
| record_format | Article |
| series | Journal of Pre-Clinical and Clinical Research |
| spelling | doaj.art-3cf67d6b422047818856a4c0ce6b965d2023-03-15T10:35:11ZengInstitute of Rural HealthJournal of Pre-Clinical and Clinical Research1898-23951898-75162020-12-0114416516810.26444/jpccr/131017131017Irreproducibility –The deadly sin of preclinical research in drug developmentSadasivan Kalathil Pillai0https://orcid.org/0000-0001-9498-1425Katsumi Kobayashi1https://orcid.org/0000-0002-3588-4526Mathews Michael2https://orcid.org/0000-0002-0268-7307Meena Arumugam3https://orcid.org/0000-0002-3983-8180International Institute of Biotechnology and Toxicology (IIBAT), Padappai, IndiaEx-Cabinet Secretary Researcher, Food Safety Commission of Japan, Akasaka, JapanTrichinopoly.i, Tiruchirappalli, IndiaK.K. College of Pharmacy, Chennai, IndiaIntroduction In recent years the irreproducibility of preclinical studies has become a serious concern in drug developmental research. The findings of preclinical studies that cannot be reproduced are a drain on public resources and slow down the drug discovery process. Among the various factors that contribute to irreproducibility in preclinical drug developmental research, poor statistical analysis and weak experimental design play a major role in the failure of drugs in clinical research. Conclusion. Poor experimental design and lack of knowledge or limited knowledge of statistical analysis of data contribute significantly to the irreproducibility of preclinical research. A well-designed experiment with proper statistical analysis of data conducted by committed researchers rarely fails to reproduce. Objective The aim of this review is to describe key factors, such as poor statistical analysis and weak experimental design, that contribute to the irreproducibility of preclinical studies in drug development, and how such studies slow down the drug development process. Brief description of the state of knowledge Theirreproducibility of preclinical research is a serious issue that researchers, especially those who are involved in drug discovery, are facing today. The irreproducibility of research drains public resources, time, and diminish the trust of the common man in the research community. The factors that contribute to the irreproducibility of preclinical research are related to experiment design and improper statistical analysis of the experimental data. Most of these factors can be eliminated by researchers developing a commitment to science and society. Conclusions Poor experimental design and lack of knowledge or limited knowledge of statistical analysis of data contribute significantly to the irreproducibility of preclinical research. A well-designed experiment with proper statistical analysis of data conducted by committed researchers rarely fails to reproduce.https://www.jpccr.eu/Irreproducibility-The-deadly-sin-of-preclinical-research-in-drug-development,131017,0,2.htmldata irreproducibilitypreclinical studiesp-values |
| spellingShingle | Sadasivan Kalathil Pillai Katsumi Kobayashi Mathews Michael Meena Arumugam Irreproducibility –The deadly sin of preclinical research in drug development Journal of Pre-Clinical and Clinical Research data irreproducibility preclinical studies p-values |
| title | Irreproducibility –The deadly sin of preclinical research in drug development |
| title_full | Irreproducibility –The deadly sin of preclinical research in drug development |
| title_fullStr | Irreproducibility –The deadly sin of preclinical research in drug development |
| title_full_unstemmed | Irreproducibility –The deadly sin of preclinical research in drug development |
| title_short | Irreproducibility –The deadly sin of preclinical research in drug development |
| title_sort | irreproducibility the deadly sin of preclinical research in drug development |
| topic | data irreproducibility preclinical studies p-values |
| url | https://www.jpccr.eu/Irreproducibility-The-deadly-sin-of-preclinical-research-in-drug-development,131017,0,2.html |
| work_keys_str_mv | AT sadasivankalathilpillai irreproducibilitythedeadlysinofpreclinicalresearchindrugdevelopment AT katsumikobayashi irreproducibilitythedeadlysinofpreclinicalresearchindrugdevelopment AT mathewsmichael irreproducibilitythedeadlysinofpreclinicalresearchindrugdevelopment AT meenaarumugam irreproducibilitythedeadlysinofpreclinicalresearchindrugdevelopment |